Login Register Cart 0
Research Article

The Relationship between Pre-miR-3131 3-bp Insertion/Deletion Polymorphism and Susceptibility and Clinicopathological Characteristics of Patients with Breast Cancer

Author(s): Mahsa Azizi, Nahid Rahimi, Gholamreza Bahari*, Seyed Mehdi Hashemi and Mohammad Hashemi

Volume 9, Issue 3, 2020

Page: [216 - 223] Pages: 8

DOI: 10.2174/2211536608666190906111830

Abstract

Aims: This study aimed at examining the effect of 3-bp pre-miR-3131 insertion/deletion (ins/del) polymorphism on Breast Cancer (BC) risk.

Objectives: Totally 403 women including 199 BC patients and 204 women who have no cancer were included in this case-control study. Genotyping of miR-3131 3-bp ins/del polymorphism was performed by mismatch PCR-RFLP method.

Methods: The findings expressed that the pre-miR-3131 3-bp ins/del variant was not related to the risk of BC in all genetic tested models. While, the ins/del genotype was related to late onset BC (OR=2.53, 95%CI=1.27-4.84, p=0.008).

Results: Pooled results from the meta-analysis indicated to that the pre-miR-3131 ins/del is related to with an increased risk of cancer in heterozygous (OR=1.26, 95%CI=1.06-1.51, p=0.01), dominant (OR=1.33, 95%CI=1.14-1.54, p=0.0002), and allele (OR=1.24, 95%CI=1.06-1.45, p=0.006) genetics models.

Conclusion: It is concluded that, our findings did not support a relationship between pre-miR-3131 ins/del polymorphism and the risk of BC. While, this variant was significantly related to late onset BC. Combined results of this study with previous studies indicated that this polymorphism increased the risk of cancer. More studies in a study with larger population with variety of ethnicities are required to verify our findings.

Keywords: Breast cancer, deletion, insertion, polymorphism, pre-miR-3131, PCR, genotype.

« Previous Next »
Graphical Abstract

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Danesh H, Hashemi M, Bizhani F, Hashemi SM, Bahari G. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene 2018; 647: 73-8.
[http://dx.doi.org/10.1016/j.gene.2018.01.025] [PMID: 29317318]
[3]
Wu J, Wang Y, Shang L, Qi L, Song M. Five common functional polymorphisms in microRNAs and susceptibility to breast cancer: an updated meta-analysis. Genet Test Mol Biomarkers 2018; 22(6): 350-8.
[http://dx.doi.org/10.1089/gtmb.2017.0270] [PMID: 29782194]
[4]
Moazeni-Roodi A, Ghavami S, Hashemi M. Association between miR-423 rs6505162 polymorphism and susceptibility to cancer. Arch Med Res 2019; 50(1): 21-30.
[http://dx.doi.org/10.1016/j.arcmed.2019.04.002] [PMID: 31101240]
[5]
Choupani J, Nariman-Saleh-Fam Z, Saadatian Z, Ouladsahebmadarek E, Masotti A, Bastami M. Association of mir-196a-2 rs11614913 and mir-149 rs2292832 polymorphisms with risk of cancer: an updated meta-analysis. Front Genet 2019; 10: 186.
[http://dx.doi.org/10.3389/fgene.2019.00186] [PMID: 30930933]
[6]
Bodal VK, Sangwan S, Bal MS, Kaur M, Sharma S, Kaur B. Association between microRNA 146a and microRNA 196a2 genes polymorphism and breast cancer risk in North Indian women. Asian Pac J Cancer Prev 2017; 18(9): 2345-8.
[PMID: 28950676]
[7]
Omrani M, Hashemi M, Eskandari-Nasab E, et al. hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomarkers Med 2014; 8(2): 259-67.
[http://dx.doi.org/10.2217/bmm.13.118] [PMID: 24521023]
[8]
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[9]
Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433(7027): 769-73.
[http://dx.doi.org/10.1038/nature03315] [PMID: 15685193]
[10]
Moazeni-Roodi A, Ghavami S, Hashemi M. Lack of association between miR-605 rs2043556 polymorphism and overall cancer risk: a meta-analysis of case-control studies. MicroRNA 2019; 8(2): 94-100.
[http://dx.doi.org/10.2174/2211536608666181204110508] [PMID: 30514199]
[11]
Wang C, Li L, Yin Z, et al. An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. Carcinogenesis 2017; 38(2): 168-76.
[http://dx.doi.org/10.1093/carcin/bgw206] [PMID: 28034876]
[12]
Dhawan A, Scott JG, Harris AL, Buffa FM. Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nat Commun 2018; 9(1): 5228.
[http://dx.doi.org/10.1038/s41467-018-07657-1] [PMID: 30531873]
[13]
Wang M, Qiu R, Gong Z, et al. miR-188-5p emerges as an oncomiRNA to promote gastric cancer cell proliferation and migration via upregulation of SALL4. J Cell Biochem 2019; 120(9): 15027-37.
[http://dx.doi.org/10.1002/jcb.28764] [PMID: 31009138]
[14]
Wu H, Xu L, Chen Y, Xu C. MiR-208a-3p functions as an oncogene in colorectal cancer by targeting PDCD4. Biosci Rep 2019; 39(4): 39.
[http://dx.doi.org/10.1042/BSR20181598] [PMID: 30914452]
[15]
Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008; 118(7): 2600-8.
[http://dx.doi.org/10.1172/JCI34934] [PMID: 18521189]
[16]
Sibin MK, Harshitha SM, Narasingarao KV, Dhananjaya IB, Dhaval PS, Chetan GK. Effect of rs11614913 polymorphism on mature miR196a2 expression and its target gene HOXC8 expression in human glioma. J Mol Neurosci 2017; 61(2): 144-51.
[http://dx.doi.org/10.1007/s12031-016-0855-z] [PMID: 27796868]
[17]
Liu F, Dear K, Huang L, et al. Association between microRNA-27a rs895819 polymorphism and risk of colorectal cancer: A meta-analysis. Cancer Genet 2016; 209(9): 388-94.
[http://dx.doi.org/10.1016/j.cancergen.2016.08.003] [PMID: 27751356]
[18]
Mullaney JM, Mills RE, Pittard WS, Devine SE. Small insertions and deletions (INDELs) in human genomes. Hum Mol Genet 2010; 19(R2): R131-6.
[http://dx.doi.org/10.1093/hmg/ddq400] [PMID: 20858594]
[19]
Hashemi M, Bahari G, Sarhadi S, et al. 4-bp insertion/deletion (rs3783553) polymorphism within the 3'UTR of IL1A contributes to the risk of prostate cancer in a sample of Iranian population. J Cell Biochem 2018; 119(3): 2627-35.
[http://dx.doi.org/10.1002/jcb.26427] [PMID: 29023981]
[20]
Hashemi M, Moazeni-Roodi A, Tabasi F, Ghavami S. 5-bp insertion/deletion polymorphism in the promoter region of LncRNA GAS5 and cancer risk: a meta-analysis of 7005 cases and 8576 controls. Meta Gene 2018; 18: 177-83.
[http://dx.doi.org/10.1016/j.mgene.2018.09.007]
[21]
Hashemi M, Bahari G, Bizhani F, et al. Evaluation of 4-bp insertion/deletion polymorphism within the 3'UTR of SGSM3 in bladder cancer using mismatch PCR-RFLP method: A preliminary report. J Cell Biochem 2018; 119(8): 6566-74.
[http://dx.doi.org/10.1002/jcb.26764] [PMID: 29693742]
[22]
Hashemi M, Bahari G, Sattarifard H, Narouie B. Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism. Mol Clin Oncol 2017; 7(4): 696-700.
[http://dx.doi.org/10.3892/mco.2017.1369] [PMID: 28856004]
[23]
Hashemi M, Sanaei S, Hashemi SM, Eskandari E, Bahari G. Association of single nucleotide polymorphisms of the MDM4 gene with the susceptibility to breast cancer in a Southeast Iranian population sample. Clin Breast Cancer 2018; 18(5): e883-91.
[http://dx.doi.org/10.1016/j.clbc.2018.01.003] [PMID: 29439926]
[24]
Hashemi M, Danesh H, Bizhani F, Sattarifard H, Hashemi SM, Bahari G. Detection of a 4-bp insertion/deletion polymorphism within the promoter of EGLN2 using mismatch PCR-RFLP and its association with susceptibility to breast cancer. Asian Pac J Cancer Prev 2018; 19(4): 923-6.
[PMID: 29693343]
[25]
Eddy SR. Non-coding RNA genes and the modern RNA world. Nat Rev Genet 2001; 2(12): 919-29.
[http://dx.doi.org/10.1038/35103511] [PMID: 11733745]
[26]
Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2001; 2(11): 986-91.
[http://dx.doi.org/10.1093/embo-reports/kve230] [PMID: 11713189]
[27]
Yang S, Sun Z, Zhou Q, et al. MicroRNAs, long noncoding RNAs, and circular RNAs: potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res 2018; 10: 2249-57.
[http://dx.doi.org/10.2147/CMAR.S166308] [PMID: 30100756]
[28]
Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012; 482(7385): 339-46.
[http://dx.doi.org/10.1038/nature10887] [PMID: 22337053]
[29]
Fernandes JCR, Acuña SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA 2019; 5(1): 5.
[http://dx.doi.org/10.3390/ncrna5010017] [PMID: 30781588]
[30]
Wang T, Xu H, Qi M, Yan S, Tian X. miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis. Oncotarget 2017; 9(4): 5473-9.
[PMID: 29435194]
[31]
van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res 2015; 17: 21.
[http://dx.doi.org/10.1186/s13058-015-0526-y] [PMID: 25849621]
[32]
Qiu X, Dou Y. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother 2017; 88: 430-5.
[http://dx.doi.org/10.1016/j.biopha.2016.11.120] [PMID: 28122308]
[33]
Kobayashi M, Saito A, Tanaka Y, et al. MicroRNA expression profiling in canine prostate cancer. J Vet Med Sci 2017; 79(4): 719-25.
[http://dx.doi.org/10.1292/jvms.16-0279] [PMID: 28239051]
[34]
Guan B, Wu K, Zeng J, et al. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget 2017; 8(5): 8162-72.
[http://dx.doi.org/10.18632/oncotarget.14131] [PMID: 28030804]
[35]
Moazeni-Roodi A, Hashemi M. Association between miR-124-1 rs531564 polymorphism and risk of cancer: An updated meta-analysis of case-control studies. EXCLI J 2018; 17: 608-19.
[PMID: 30108465]
[36]
Moazeni-Roodi A, Bahari G, Taheri M, Ansari H, Hashemi M. Association between miR-218 rs11134527 polymorphism and risk of selected types of cancer in Asian population: An updated meta-analysis of case-control studies. Gene 2018; 678: 370-6.
[http://dx.doi.org/10.1016/j.gene.2018.08.053] [PMID: 30120974]
[37]
Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumour Biol 2014; 35(1): 219-25.
[http://dx.doi.org/10.1007/s13277-013-1027-1] [PMID: 23888320]
[38]
Hashemi M, Sanaei S, Mashhadi MA, Hashemi SM, Taheri M, Ghavami S. Association study of hsa-mir-603 rs11014002 polymorphism and risk of breast cancer in a sample of Iranian population. Cell Mol Biol 2015; 61(8): 69-73.
[PMID: 26718432]
[39]
Hashemi M, Sanaei S, Rezaei M, et al. miR-608 rs4919510 C>G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. Exp Oncol 2016; 38(1): 57-9.
[http://dx.doi.org/10.31768/2312-8852.2016.38(1):57-59] [PMID: 27031722]
[40]
Sanaei S, Hashemi M, Rezaei M, Hashemi SM, Bahari G, Ghavami S. Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk. Biomed Rep 2016; 5(1): 125-9.
[http://dx.doi.org/10.3892/br.2016.690] [PMID: 27347415]
[41]
Shen J, Park HS, Xia YM, Kim GS, Cui SW. The polysaccharides from fermented Ganoderma lucidum mycelia induced miRNAs regulation in suppressed HepG2 cells. Carbohydr Polym 2014; 103: 319-24.
[http://dx.doi.org/10.1016/j.carbpol.2013.12.044] [PMID: 24528735]
[42]
Polytarchou C, Hommes DW, Palumbo T, et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology 2015; 149: 981-2.
[http://dx.doi.org/10.1053/j.gastro.2015.05.057]
[43]
Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466(7308): 835-40.
[http://dx.doi.org/10.1038/nature09267] [PMID: 20703300]
[44]
Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10(6): 389-402.
[http://dx.doi.org/10.1038/nrc2867] [PMID: 20495573]
[45]
Thakur N, Singhal P, Mehrotra R, Bharadwaj M. Impacts of single nucleotide polymorphisms in three microRNAs (miR-146a, miR-196a2 and miR-499) on the susceptibility to cervical cancer among Indian women. Biosci Rep 2019; 39(4): 39.
[http://dx.doi.org/10.1042/BSR20180723] [PMID: 30872409]
[46]
Hashemi M, Moazeni-Roodi A, Bahari G, Taheri M, Ghavami S. Association between miR-34b/c rs4938723 polymorphism and risk of cancer: An updated meta-analysis of 27 case-control studies. J Cell Biochem 2019; 120(3): 3306-14.
[http://dx.doi.org/10.1002/jcb.27598] [PMID: 30203457]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy